Research programme: antimalarial implants - Titan Pharmaceuticals
Alternative Names: Atovaquone implant; Doxycycline implant; Piperaquine implant; ProNeura™ antimalarial implants; ProNeura™ antimalarial implants - Titan; ProNeura™ atovaquone implant; ProNeura™ doxycycline implant; ProNeura™ piperaquine implantLatest Information Update: 28 Aug 2021
Price :
$50 *
At a glance
- Originator Titan Pharmaceuticals
- Class Antimalarials; Piperazines; Quinolines; Small molecules; Tetracyclines
- Mechanism of Action Electron transport complex I inhibitors; Hemozoin inhibitors; Protein 30S ribosomal subunit inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Malaria in USA (SC, Implant)
- 06 Jul 2017 Titan Pharmaceuticals establishes CRADA with the Walter Reed Army Institute of Research and Southwest Research Institute for the development of ProNeura™ based implants in Malaria
- 06 Jul 2017 Preclinical trials in Malaria in USA (SC)